Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28605103 | 1.00 | HIF1A (0.40) | HIF1AMAPTPDE4AKDRCHRNB2 | |
| Piperazine SCHEMBL28017070 | 0.97 | HIF1A (0.38) | HIF1AMAPTPDE4AKDRCHRNB2 | |
| Piperazine SCHEMBL27991446 | 0.97 | HIF1A (0.38) | HIF1AMAPTPDE4AKDRCHRNB2 | |
| Piperazine SCHEMBL27985317 | 0.97 | HIF1A (0.38) | HIF1AMAPTPDE4AKDRCHRNB2 | |
| Piperidine SCHEMBL28992046 | 0.89 | ALDH1A1 (0.47) | HIF1AMAPTPDE4AKDRCHRNB2 | |
| Piperazine SCHEMBL3951824 | 0.89 | TSHR (0.33) | HIF1AMAPTPDE4AKDRCHRNB2 | |
| Pyrimidine SCHEMBL20897915 | 0.88 | TSHR (0.30) | TSHRNAPRTTDP1 | |
| Pyrimidine SCHEMBL21046656 | 0.88 | ALDH1A1 (0.44) | CHRNB2CHRNA4CXCR4SMN1; SMN2TSHR | |
| Piperazine SCHEMBL28203228 | 0.87 | HIF1A (0.30) | HIF1AMAPTPDE4AKDR | |
| Piperidine SCHEMBL1385062 | 0.85 | ALDH1A1 (0.50) | CHRNB2CHRNA4CXCR4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114414707-B | Method and kit for detecting 19 drugs and metabolites thereof in blood by liquid chromatography tandem mass spectrometry | 北京和合医学诊断技术股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-113024536-B | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2022-05-27 | — | — | CN | claimed |
| CN-114414707-A | Method and kit for detecting 19 drugs and metabolites thereof in blood by liquid chromatography tandem mass spectrometry | 北京和合医学诊断技术股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-113248518-B | Pyrimidine piperazine derivative and preparation method and application thereof | 山东大学 | 2022-03-25 | — | — | CN | claimed |
| CN-113248518-A | Pyrimidine piperazine derivative and preparation method and application thereof | 山东大学 | 2021-08-13 | — | — | CN | claimed |
| CN-113024536-A | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2021-06-25 | — | — | CN | claimed |
| CN-107365274-B | pyrimidine piperazine amide compound and application thereof | 广州医大科技发展有限公司 | 2019-11-26 | — | — | CN | claimed |
| US-10433544-B2 | Herbicide | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-10-08 | — | — | US | claimed |
| CN-109517594-A | Electroluminescent organic material and device | 环球展览公司 | 2019-03-26 | — | — | CN | claimed |
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2019-03-12 | — | — | US | claimed |
| WO-2016123627-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOUNDS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2016-08-04 | — | — | WO | claimed |
| WO-2016115272-A1 | BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2016-07-21 | — | — | WO | claimed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| CN-102245024-A | Inhibitors of diacylglycerol aclytransferase | VIA PHARMACEUTICALS INC | 2011-11-16 | — | — | CN | claimed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | claimed |
| US-7629364-B2 | Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments | CANBAS CO., LTD. (JP) | 2009-12-08 | — | — | US | claimed |
| CN-101318935-A | Method for preparing hydrochloric 1-(2-pyrimidine) diethylenediamine compound | NANTONG KANGXING PHARMACEUTICA (CN) | 2008-12-10 | — | — | CN | claimed |
| CN-101316901-A | Dye-attached and/or surface-modified pigments | SOANE LAB LLC (US) | 2008-12-03 | — | — | CN | claimed |
| US-20080293137-A1 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CANBAS CO., LTD. (JP) | 2008-11-27 | — | — | US | claimed |
| CN-101250184-A | Method for synthesizing 1-(2-pyrimidine) piperazine | TAICANG QIANJING CHEMICAL INDU (CN) | 2008-08-27 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293137-A1 | COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS | CDC25C, CHEK1, CDC25A | HIF1A 756/4885MAPT 4441/4885PDE4A 1739/4885 |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT2, DGAT1, ACAT2 | HIF1A 3758/4885MAPT 3731/4885PDE4A 781/4885 |
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRIA4, GRM4, GRIK4 | HIF1A 3879/4885MAPT 984/4885PDE4A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.